Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic Malignancies.

IF 11.5 Q1 HEMATOLOGY

Blood Cancer Discovery Pub Date : 2023-05-01 DOI:10.1158/2643-3230.BCD-22-0213

Laurence Zitvogel, Lisa Derosa, Guido Kroemer

引用次数: 0

Abstract

Summary: In patients with multiple myeloma, completion of mRNA-based vaccination schemes failed to yield detectable SARS-CoV-2 Omicron-neutralizing antibodies and S1-RBD-specific CD8+ T cells in approximately 60% and 80% of the cases, respectively. Patients who develop breakthrough infections exhibited very low levels of live-virus neutralizing antibodies and the absence of follicular T helper cells. See related article by Azeem et al., p. 106 (9). See related article by Chang et al., p. 1684 (10).

查看原文本刊更多论文

尽管在血液系统恶性肿瘤中完全接种了疫苗，但对严重急性呼吸系统综合征冠状病毒2型奥密克戎变异株的免疫力有缺陷。

摘要：在多发性骨髓瘤患者中，分别约60%和80%的病例中，完成基于信使核糖核酸的疫苗接种方案未能产生可检测的严重急性呼吸系统综合征冠状病毒2型奥密克戎中和抗体和S1 RBD特异性CD8+T细胞。出现突破性感染的患者表现出非常低水平的活病毒中和抗体，并且缺乏卵泡T辅助细胞。见Azeem等人的相关文章，第106（9）页。见Chang等人的相关文章，第1684（10）页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.